Waning Time of Maternally Derived Anti-Hepatitis A and Anti-Varicella Zoster Virus Antibodies

2019 ◽  
Vol 14 (03) ◽  
pp. 116-120
Author(s):  
Aysu Duyan Camurdan ◽  
Ufuk Beyazova ◽  
Gulendam Bozdayı ◽  
Fusun Civil ◽  
Aylin Altay Kocak ◽  
...  
Keyword(s):  
Cord Blood ◽  
Hepatitis A ◽  
Immunoglobulin M ◽  
University Hospital ◽  
Optimal Time ◽  
Enzyme Linked Immunosorbent Assay ◽  
Igg Antibodies ◽  
Blood Samples ◽  
Varicella Zoster ◽  
Healthy Infants

Objective The objective of this study was to investigate the persistence of maternally derived antibodies to hepatitis A (anti-HAV) and varicella zoster (anti-VZV) viruses to determine the optimal time of vaccination of infants. Materials and Methods This study was conducted between 2011 and 2012 at the Gazi University Hospital. Blood samples were collected from healthy infants' cord blood and at 12th, 18th, and 24th months of age. Anti-HAV and anti-VZV immunoglobulin M (IgM) and immunoglobulin G (IgG) antibodies were measured by enzyme-linked immunosorbent assay kit in blood samples. Results A total of 546 infants and children were included in the study; all had blood samples taken at four time points (at birth [cord blood], and at 12, 18, and 24 months). Anti-HAV IgG seropositivity rates in these samples were 77.3, 29.6, 14.8, and 17.7%, respectively (p < 0.05). Corresponding anti-VZV IgG seropositivity rates were 83.3, 21.5, 29.5, and 33.8%, respectively (p < 0.05). Conclusion Anti-HAV and anti-VZV seropositivity rates were lowest at 18 and 12 months, respectively. We suggest that if VZV and hepatitis A vaccines were included in the national vaccination program after the age of 1 year, there should be little interference from passively acquired maternal antibodies.

scholarly journals Seropositivity of Dengue Antibodies during Pregnancy

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
Nor Azlin Mohamed Ismail ◽  
Wan Elly Rushima Wan Abd Rahim ◽  
Sharifah Azura Salleh ◽  
Hui-Min Neoh ◽  
Rahman Jamal ◽  
...  
Keyword(s):  
Cord Blood ◽  
Maternal Age ◽  
Neonatal Intensive Care ◽  
Detrimental Effect ◽  
Enzyme Linked Immunosorbent Assay ◽  
Igg Antibodies ◽  
Endemic Country ◽  
Blood Samples ◽  
Recorded Data ◽  
Nicu Admission

Purpose. Malaysia a dengue endemic country with dengue infections in pregnancy on the rise. The present study was aimed at determining dengue seroprevalence (IgG or IgM) during pregnancy and its neonatal transmission in dengue seropositive women.Methods. Maternal with paired cord blood samples were tested for dengue antibodies (IgG and IgM) using an enzyme-linked immunosorbent assay (ELISA). Maternal age, parity, occupation, ethnic group, and gestational age were recorded. Data on neonatal Apgar score and admissions to the Neonatal Intensive Care Unit (NICU) were analyzed.Results. Out of 358 women recruited, about 128 (35.8%) patients were seropositive. Twelve patients (3.4%) had recent infections (IgM positive) and another 116 women (32.4%) were with past infections (IgG positive). All babies born to seropositive mothers had positive IgG paired cord blood; however, no IgM seropositivity was observed. All neonates had good Apgar scores and did not require NICU admission.Conclusion. In this study, 35.8% pregnant women were found to be dengue seropositive. However, transplacental transfer of IgG antibodies had no detrimental effect on the neonatal outcomes.

Measles antibodies and response to vaccination in children aged less than 14 months: implications for age of vaccination

2011 ◽  
Vol 140 (9) ◽  
pp. 1599-1606 ◽  
Author(s):  
E. BORRÀS ◽  
L. URBIZTONDO ◽  
J. COSTA ◽  
J. BATALLA ◽  
N. TORNER ◽  
...  
Keyword(s):  
Immunosorbent Assay ◽  
Maternal Antibodies ◽  
Passive Immunity ◽  
Enzyme Linked Immunosorbent Assay ◽  
Igg Antibodies ◽  
Blood Samples ◽  
Measles Outbreak ◽  
Measles Antibodies ◽  
Measles Vaccination

SUMMARYPassive immunity against measles decreases during the first months of life. The objective of this study was to determine titres of measles antibodies in children aged 9–14 months and their mothers before vaccination, and the children's response to vaccination. Blood samples were collected by capillary puncture before and 28 days after vaccination. Samples were obtained between February and June 2007 during an ongoing measles outbreak. Titres of specific measles IgG antibodies were determined by enzyme-linked immunosorbent assay. Seroconversion was defined as the presence of antibodies after vaccination in subjects without antibodies before vaccination. Maternal antibodies were present in 37·7% of all 69 children included and in 45·1% of children aged 9 months. Of the 51 children in whom a second sample was obtained, 31 (60·8%) were seronegative before vaccination and 61·3% seroconverted. Interference of maternal antibodies was 30%. Advancing the first dose of measles vaccination from 15 to 12 months is a correct strategy, given the increase in the time of susceptibility of infants to measles.

scholarly journals Detection of cross-reactive IgA against SARS-CoV-2 spike 1 subunit in saliva

2021 ◽  
Author(s):  
Keiichi Tsukinoki ◽  
Tatsuo Yamamoto ◽  
Keisuke Handa ◽  
Mariko Iwamiya ◽  
Juri Saruta ◽  
...  
Keyword(s):  
Breast Milk ◽  
Recombinant Protein ◽  
University Hospital ◽  
Spike Protein ◽  
Secretory Iga ◽  
Enzyme Linked Immunosorbent Assay ◽  
Receptor Binding Domain ◽  
Blood Samples ◽  
Milk Samples ◽  
Mucosal Surfaces

AbstractAbundant secretory IgA (sIgA) in mucus, breast milk, and saliva provides immunity that prevents infection of mucosal surfaces. sIgA in pre-pandemic breast milk samples have been reported to cross-react with SARS-CoV-2, but whether it also occurs in saliva and, if so, whether it cross-reacts with SARS-CoV-2, has remained unknown. We aimed to clarify whether sIgA in saliva cross-reacts with SARS-CoV-2 spike 1 subunit in individuals who have not been infected with this virus. The study included 137 (male, n = 101; female, n = 36; mean age, 38.7 [24–65] years) of dentists and doctors in the Kanagawa Dental University Hospital. Saliva and blood samples were analyzed by PCR and immunochromatography for IgG and IgM, respectively. We then identified patients with saliva samples that were confirmed as PCR- and IgM-negative for COVID-19. Proportions of SARS-CoV-2 cross-reactive IgA-positive individuals were determined by enzyme-linked immunosorbent assay using a biotin-labeled spike S1-mFc recombinant protein covering the receptor-binding domain of SARS-CoV-2. The proportion of SARS-CoV-2 cross-reactive IgA-positive individuals was 46.7%, and this correlated negatively with age (r = −0.218, p = 0.01). The proportion of IgA-positive individuals ≥ 50 y was significantly lower than that of patients aged ≤ 49 y (p = 0.008). sIgA was purified from the saliva of all patients, and the salivary sIgA was found to suppress the binding of SARS-CoV-2 spike protein to the ACE-2 receptor. We found SARS-CoV-2 cross-reactive sIgA in the saliva of some participants who had never been infected with the virus, suggesting that sIgA helps prevent SARS-CoV-2 infection.

Immunodiagnosis and molecular validation of Toxoplasma gondii infection among patients with end-stage renal disease undergoing haemodialysis

Parasitology ◽  
2019 ◽  
Vol 146 (13) ◽  
pp. 1683-1689 ◽  
Author(s):  
Zahra Arab-Mazar ◽  
Shirzad Fallahi ◽  
Davood Yadegarynia ◽  
Amirreza Javadi Mamaghani ◽  
Seyyed Javad Seyyed Tabaei ◽  
...  
Keyword(s):  
Toxoplasma Gondii ◽  
Renal Disease ◽  
End Stage Renal Disease ◽  
Immunoglobulin M ◽  
Enzyme Linked Immunosorbent Assay ◽  
Healthy Controls ◽  
Blood Samples ◽  
Igm Antibodies ◽  
Stage Renal Disease ◽  
End Stage

AbstractInfection is a significant cause of morbidity and mortality in patients with chronic kidney disease, especially who were under dialysis due to their depressed immunity. Toxoplasma gondii is a ubiquitous parasite that causes severe manifestations in immunocompromised patients. This case-control study was conducted to the immunodiagnosis and molecular validation of T. gondii infection among patients with end-stage renal disease undergoing haemodialysis. The study population consisted of 260 haemodialysis patients and 259 healthy controls referred to the main dialysis centres of Tehran, Iran during 2016. Anti-T. gondii immunoglobulin G (IgG) and immunoglobulin M (IgM) antibodies were assessed using enzyme-linked immunosorbent assay. As well, the T. gondii genomic DNA in whole blood samples of IgM-positive patients and healthy controls was evaluated using GRA6-polymerase chain reaction (PCR) and SAG1-loop-mediated isothermal amplification (LAMP) assays. The anti-T. gondii IgG and IgM antibodies were detected in 175 (67.3%) and 18 (7%) of haemodialysis patients and 122 (47%) and 4 (1.5%) of controls, respectively. Two of the 18 blood samples from IgM-positive patients and none of the IgM-positive control subjects were positive by GRA6-PCR. Whereas, nine and two blood samples of IgM-positive patients and controls were positive for Toxoplasma DNA by a SAG1-LAMP technique respectively. The seropositivity of the Toxoplasma IgM antibody was significantly different between haemodialysis patients and healthy controls which was confirmed by PCR and LAMP. The higher prevalence of T. gondii infection in haemodialysis patients compared with the controls proposes that these patients can be a group at risk for toxoplasmosis and screening for toxoplasmosis before dialysis is necessary for the patients.

scholarly journals The distribution of antibodies to HHV-6 compared with other herpesviruses in young children

1990 ◽  
Vol 105 (3) ◽  
pp. 603-607 ◽  
Author(s):  
T. J. Farr ◽  
G. B. Harnett ◽  
G. R. Pietroboni ◽  
M. R. Bucens
Keyword(s):  
Young Children ◽  
Cord Blood ◽  
Western Australia ◽  
Age Groups ◽  
The Other ◽  
Early Age ◽  
Rapid Rise ◽  
Igg Antibodies ◽  
Blood Samples ◽  
Igm Antibodies

SUMMARYSera from 141 infants aged 0–12 months were examined for IgG antibodies to HHV-6, HSV, CMV, VZV and EBV and for HHV-6 specific IgM. Following the decline in maternal antibody, antibody to HHV-6 was found to rise by 5–6 months and approached the level found in adults by 11–12 months. In contrast the antibody rates for the other herpesviruses were much slower to rise, especially in the case of CMV and EBV. HHV-6 IgM antibodies were detected mainly in age groups showing a rapid rise in antibody to HHV-6. HHV-6-IgM was not detected in 235 cord blood samples. The data suggest that HHV-6 infection is acquired horizontally, at a very early age in Western Australia.

scholarly journals Evaluation of anti-SARS-CoV-2 antibody testing in asymptomatic or mild COVID-19 patients in outbreak on a cruise ship

2021 ◽  
Author(s):  
Norihito Kaku ◽  
Fumitaka Nishimura ◽  
Yui Shigeishi ◽  
Rina Tachiki ◽  
Hironori Sakai ◽  
...  
Keyword(s):  
Genetic Test ◽  
False Negative ◽  
Enzyme Linked Immunosorbent Assay ◽  
Cruise Ship ◽  
Igg Antibodies ◽  
Antibody Testing ◽  
Predictive Values ◽  
Blood Samples ◽  
Negative Results ◽  
Genetic Test Results

AbstractBackgroundA few studies on antibody testing have focused on asymptomatic or mild coronavirus disease 2019 (COVID-19) patients with low initial anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibody responses. Anti-SARS-CoV-2 antibody-testing performance was evaluated using blood samples from asymptomatic or mild COVID-19 patients.MethodsBlood samples were collected from 143 COVID-19 patients during an outbreak on a cruise ship 3 weeks after diagnosis. Simultaneously, a second SARS-CoV-2 genetic test was performed. Samples stored before the COVID-19 pandemic were also used to evaluate the lateral flow immunochromatographic assay (LFA) and electrochemiluminescence immunoassay (ECLIA). Titers of anti-SARS-CoV-2 IgM and IgG antibodies against the nucleocapsid and spike proteins were measured using the enzyme-linked immunosorbent assay to compare false-negative- with positive-result samples.ResultsSensitivity, specificity, positive-predictive, and negative-predictive values of LFA-detected IgM antibodies were 0.231, 1.000, 1.000, and 0.613, respectively; those of LFA-detected IgG antibodies were 0.483, 0.989, 0.972, and 0.601, respectively; and those of ECLIA-detected total antibodies were 0.783, 1.000, 1.000, and 0.848, respectively. IgM-, IgG-, and total-antibody positivity rates in the patients with negative results from the second genetic testing were 22.9%, 47.6%, and 72.4%, respectively. All antibody titers, especially those of the IgG antibody against nucleocapsid protein, were significantly lower in blood samples with false-negative results than in those with positive results.ConclusionsThese findings suggest that anti-SARS-CoV-2 antibody testing has lower performance in asymptomatic or mild COVID-19 patients than required in the guidelines, and situations in which it is useful are limited.Key pointsAnti-SARS-CoV-2 antibody testing in asymptomatic or mild COVID-19 patients is lower than the required clinical sensitivity, although it may be useful in patients at 3–4 weeks after symptom onset but with negative SARS-CoV-2 genetic test results.

scholarly journals Development of a Bead-Based Multiplex Immunoassay for Simultaneous Quantitative Detection of IgG Serum Antibodies against Measles, Mumps, Rubella, and Varicella-Zoster Virus

2012 ◽  
Vol 19 (3) ◽  
pp. 396-400 ◽  
Author(s):  
Gaby P. Smits ◽  
Pieter G. van Gageldonk ◽  
Leo M. Schouls ◽  
Fiona R. M. van der Klis ◽  
Guy A. M. Berbers
Keyword(s):  
Varicella Zoster Virus ◽  
High Specificity ◽  
Good Alternative ◽  
Multiplex Assay ◽  
Quantitative Detection ◽  
Enzyme Linked Immunosorbent Assay ◽  
Igg Antibodies ◽  
Multiplex Immunoassay ◽  
Varicella Zoster ◽  
Elisa Kit

ABSTRACTEnzyme-linked immunosorbent assay (ELISA) is normally used to quantify the amount of serum IgG antibodies against measles, mumps, rubella, and varicella-zoster virus (MMRV). However, this method is time- and material-consuming. Therefore, a multiplex immunoassay for the simultaneous quantitative detection of antibodies against MMRV was developed. In-house as well as commercially available antigens can be used, making the assay available for all laboratories. The multiplex assay is much more sensitive than the separate ELISAs and has a high specificity, and only 5 μl of serum is needed. Heterologous inhibition did not exceed 11.5%, while homologous inhibition varied between 91.3 and 97.9%. Good correlations with the in-house ELISAs for measles (R2= 0.98), mumps (R2= 0.97), and rubella (R2= 0.97) virus as well as with the ELISA kit for varicella-zoster virus (R2= 0.95) were obtained. In conclusion, the MMRV multiplex assay is a good alternative to the conventional ELISAs and suitable for use in serosurveillance and vaccine studies.

scholarly journals Validity of Self-Reported Varicella Disease History in Pregnant Women Attending Prenatal Clinics

2007 ◽  
Vol 122 (4) ◽  
pp. 499-506 ◽  
Author(s):  
Barbara Watson ◽  
Rachel Civen ◽  
Meredith Reynolds ◽  
Karl Heath ◽  
Dana Perella ◽  
...  
Keyword(s):  
Pregnant Women ◽  
Strong Predictor ◽  
Varicella Vaccine ◽  
Routine Care ◽  
Varicella Vaccination ◽  
Enzyme Linked Immunosorbent Assay ◽  
Igg Antibodies ◽  
Serological Evidence ◽  
Varicella Zoster ◽  
Cell Enzyme

Objective. The purpose of this study was to assess the validity of self-reported history for varicella disease relative to serological evidence of varicella immunity in pregnant women attending antenatal care at clinics located in two diverse geographical locations in the U.S. (Antelope Valley, California, and Philadelphia) with high varicella vaccination coverage. Methods. Pregnant women attending prenatal care appointments who needed blood drawn as part of their routine care were eligible to participate. Self-reported varicella disease history was obtained via questionnaire. Varicella serostatus was determined using a whole-cell enzyme-linked immunosorbent assay to test for varicella zoster virus-specific immunoglobulin G (VZV IgG) antibodies. Results. Of the 309 study participants from Antelope Valley and the 528 participants from Philadelphia who self-reported having had chickenpox disease, 308 (99.7%; 95% confidence interval [CI]: 98.2, 100) and 517 (97.9%; 95% CI: 96.3, 99.0), respectively, had serological evidence of immunity to varicella. Only 6.8% (95% CI: 3.9, 11.0) and 17.4% (95% CI: 13.1, 22.5) of women who self-reported having a negative or uncertain varicella disease history in Antelope Valley and Philadelphia, respectively, were seronegative for varicella antibodies. Conclusion. Despite the dramatic changes in the epidemiology of varicella that have occurred since 1995 due to the introduction and subsequent widespread use of the varicella vaccine, self-reported history of varicella continues to be a strong predictor of VZV IgG antibodies in pregnant women. Negative or uncertain history remains poorly predictive of negative serostatus.

Sign in / Sign up

Export Citation Format

Share Document